Kardigan Reports Q3 2026 Financials, Robust Cash Position
Kardigan completed enrollment in Phase 2b studies and expects critical clinical data readouts in 2027, using its $591.4 million cash position to fund advanced late-stage cardiac programs.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed